Foolish bottom line
These are just three things I picked out that will be moving Pfizer stock in the next several months. A successful separation from Zoetis Inc (NYSE:ZTS) will show investors that management is focused on higher-margin pharmaceutical products. Likewise, expanding Prevnar13 to the rest of the population would give the company the de facto pneumococcal vaccine, perhaps boosting the bottom line as early as the end of the year. If Xeljanz can find stable footing of its own, Pfizer Inc. (NYSE:PFE) stock could be driven higher by three powerful catalysts. The world’s largest pharma company may be complex, but all-in-all the future looks bright for long-term investors.
The article 3 Things About to Move Pfizer Stock originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio or his CAPS page, or follow him on Twitter, @BlacknGoldFool, to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool has no position in any of the stocks mentioned.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.